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Among 472 patients with human immunodeficiency virus-
associated cryptococcal meningitis, 16% had severe visual 
loss at presentation, and 46% of these were 4-week survivors 
and remained severely impaired. Baseline cerebrospinal fluid 
opening pressure  ≥40  cmH2O (adjusted odds ratio [aOR], 
2.56; 95% confidence interval [CI], 1.36–4.83; P  =  .02) and 
fungal burden  >6.0 log10 colonies/mL (aOR, 3.01; 95% CI, 
1.58–5.7; P  =  .003) were independently associated with se-
vere visual loss.
Keywords.  cryptococcal meningitis; fungal burden; HIV; 
raised intracranial pressure; visual loss.
Human immunodeficiency virus (HIV)-associated crypto-
coccal meningitis (CM) is the most common cause of adult 
meningitis in sub-Saharan Africa, and it accounts for ~180 000 
deaths/year globally [1]. In addition to headache, CM often 
presents with altered mental status, raised intracranial pres-
sure (ICP), and hearing and visual loss [2], with survivors often 
experiencing neurological sequelae [3–5]. In CM, visual loss 
is usually bilateral, can be sudden or gradual in onset, occurs 
before or during antifungal treatment, and—especially without 
intervention—is frequently irreversible [3, 5, 6]. Evaluation of 
visual acuity in encephalopathic patients is challenging: the few 
CM cohorts (HIV and non-HIV) that systematically examined 
visual acuity report a prevalence of 33%–46% for any visual 
impairment (<6/6 Snellen chart), with profound visual loss 
(<6/60) occurring in 13% of patients [5–7].
Proposed mechanisms of visual loss include direct optic 
nerve infiltration by cryptococci (demonstrated on autopsy 
as well as tissue biopsy), inflammatory arachnoiditis, or optic 
nerve compression through raised ICP or a more localized optic 
nerve compartment syndrome [5], with both fungal burden 
and raised ICP implicated in its pathophysiology [3, 8]. Prior, 
small retrospective cohorts (<100 patients) suggested that high 
fungal burden (cerebrospinal fluid [CSF] cryptococcal an-
tigen titer  >1024) or raised ICP (CSF opening pressure [OP] 
>30 cmH2O) are associated with visual loss in CM, but they have 
been too small to undertake multivariable analyses [3, 6]. In this 
study, we report on the prevalence, risk factors, and reversibility 
of visual loss in a large prospective CM patient multicountry 
cohort in sub-Saharan Africa [9].
METHODS
Anonymized data from the Advancing Cryptococcal Meningitis 
Treatment in Africa ([ACTA] ISCRTN 45035509) trial formed 
the dataset for this preplanned substudy [9]. Between 2013 and 
2016, 678 adults with HIV CM were randomized to receive oral 
fluconazole plus flucytosine or amphotericin B-based therapy 
for 1 or 2 weeks. Patients had protocol-specified lumbar punc-
tures (LPs) on day 1, 7, and 14 with OP measurements and ther-
apeutic CSF drainage according to guidelines [10].
Visual acuity (VA) was measured at baseline (≤3 days from 
enrollment) and at 4 weeks using the standardized logMAR 
chart in surviving patients whose conscious level permitted 
assessment. The score, ranging from 0 (able to read all letters 
on the smallest line) to 1.375 (unable to read any letters), was 
recorded for each eye. Those unable to read any letters were as-
sessed for finger counting, hand movement, and light percep-
tion. Those without light perception were considered blind. 
Patients were classified into 6 categories: (1) near-normal vision 
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(score <0.5), (2) moderate visual loss (score ≥0.5 but <1.0), (3) 
finger counting (score ≥1.0 and able to count fingers), (4) hand 
motion perception, (5) light perception, or (6) no light percep-
tion. When VA varied between the left and right eye (9.3%, 44 
of 472), data for the worst eye were analyzed. Patients did not 
routinely undergo computed tomography brain or fundoscopy 
to assess for papilloedema or other ocular pathology.
Data were analyzed using Stata v15 (StataCorp, College Station, 
Texas, United States), using Kruskal-Wallis tests for continuous 
variables, chi-squared tests for categorical variables and quantile 
regression to test for trend across the 6 visual acuity categories. 
Based on proposed pathophysiological mechanisms, univariable 
and multivariable logistic regression was used to investigate the 
association between baseline visual loss and CSF white cell count 
(WCC), OP, and fungal burden, adjusted a priori for age. Sex, CD4 
count, and antiretroviral therapy status (naive or exposed) were not 
associated with visual loss, and no other measured variables were 
hypothesized to confound the relationship. For analysis of the as-
sociation among VA, CSF, OP, and fungal burden, VA was dichot-
omized into near-normal/moderate vision (categories 1 and 2) and 
severe visual loss (categories 3–6), similar to definitions in [4].
To assess impact of antifungal therapy and therapeutic LPs 
on reversibility of visual impairment, rate of clearance of in-
fection, number of LPs performed, total CSF volume removed, 
and change in OP over 2 weeks’ treatment was compared (1) 
between those with repeat measurements at 4 weeks in whom 
acuity deteriorated and those who improved and (2) in those 
that remained severe versus improved from severe.
Patient Consent Statement
Written informed consent was obtained from all participants 
in ACTA. Ethical approval was granted by the London School 
of Hygiene and Tropical Medicine Research Ethics Committee 
and by national research ethics committees and regulatory 
bodies in Malawi, Zambia, Cameroon, and Tanzania.
RESULTS
Baseline Data
Of 678 ACTA participants, VA was measured in 472 (69.6%) 
at baseline. Seventy-five patients (15.9%) had severe visual loss 
with 20 (4%) classed as blind. One fifth (15 of 75) of those with 
severe visual loss also reported hearing loss.
Overall, 206 (47.1%) patients had raised baseline ICP 
(OP ≥25 cmH2O) and median fungal burden was 4.9 log10 colo-
nies/mL (interquartile range, 3.7–5.8) (Supplementary Table 1). 
Cryptococcus neoformans was the predominant species causing 
CM in this African cohort (337 of 382 sequenced isolates). Due 
to difficulties in measuring VA in unconscious patients, the 
VA cohort had less abnormal mental status (Glasgow Coma 
Scale <15) (12.5% vs 50.5%, P < .001) and lower median OP (19 
vs 25 cmH2O, P < .001), but no significant differences in median 
fungal burden (4.9 vs 5.1 log10 colonies/mL, P = .74), compared 
with the entire trial cohort.
Association Among Severe Baseline Visual Loss, Opening Pressure, and 
Fungal Burden
Across 6 categories from near-normal to blind, decreasing 
VA was associated with both increased OP and higher fungal 
burden at baseline (P = .02 and P < .008, respectively) (Figure 1a 
and b). High OP and fungal burdens were also associated, with 
55 (25.6%) patients with fungal burden above the median (≥4.9 
log10 colonies/mL) also experiencing high OP (>40  cmH2O), 
compared with 33 (15.4%) with lower fungal burden (P = .009).
In multivariable analyses, age, baseline CSF pressure (<25 cm 
vs ≥40  cmH2O [adjusted odds ratio {aOR}, 2.56; 95% confi-
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Figure 1. (a) Box plot (median, interquartile range, range) of baseline cerebrospinal fluid (CSF) opening pressure by visual acuity group at presentation. (b) Box plot of base-
line fungal burden by visual acuity group at presentation. CF, count fingers; HM, hand motion; LP, light perception; ML, moderate loss; NN, near normal; NNV, near-normal 
vision; NV, no vision (blind); PL, perceives light.
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([<5 vs >6.0 log10 colonies/mL] aOR, 3.01; 95% CI, 1.58–5.7; 
P = .003) were independently associated with severe visual loss 
(Table 1). There was no association between baseline central 
nervous system inflammation (CSF WCC  >10  × 109/L) and 
visual loss on either univariable or multivariable analyses.
Changes in Visual Acuity Over Time
Paired VA data were available for 336 of 472 (71.2%) patients at 
baseline and week 4. Of these, 171 (50.9%) had normal vision, 
128 (38.1%) had moderate vision, and 37 (11.0%) had severe 
visual loss at baseline. Death before follow-up was the main 
reason for missing data at 4 weeks (98 of 136, 72.1%).
Visual acuity remained unchanged over time for 210 (62.5%) 
patients. No significant differences were observed in rate of clear-
ance of infection, number of LPs performed, total volume of CSF 
removed, and change in OP over the first 2 weeks of treatment be-
tween the group remaining the same, those in whom VA deteri-
orated (n = 51, 15.2%), and those that improved (n = 75, 22.3%) 
(P > .1, all comparisons) (Supplementary Table 2).
Of 37 (11%) patients with severe visual loss at baseline, 12 
(32.4%) improved to near-normal, 8 (21.6%) improved to 
moderate, and 17 (46.0%) remained severe. Again, there were 
no significant differences in the above parameters between 
patients remaining severely impaired and those improving 
(Supplementary Table 3), although numbers for comparison 
were low.
DISCUSSION
This prospective study within a large African trial is the first 
to demonstrate an independent association of both fungal 
burden and raised ICP, in addition to age, with visual loss 
at presentation with HIV-CM. At presentation, 16% of pa-
tients had severe visual loss and 4% were blind: in those with 
repeat measurements at 4 weeks, after fungicidal treatment 
regimens and aggressive management of raised ICP, 54% of 
patients with severe baseline visual loss improved to near-
normal or moderate vision, whereas 46% remained severely 
impaired.
In a case series comprising both HIV-infected and unin-
fected patients (n  =  49), the authors proposed dichotomous 
mechanisms of visual loss, optic neuritis due to fungal infil-
tration accounting for early rapid visual loss, and optic nerve 
compression due to raised ICP accounting for a slower onset. 
Interventions aimed at reducing ICP were the only ones asso-
ciated with any success [3]. In a study of immunocompetent 
adults with Cryptococcus gattii meningitis, in which ICP was 
not consistently measured or managed, 37% of 57 survivors re-
mained blind, compared with 5% in our cohort [6]. The uni-
formity of our cohort, in terms of use of fungicidal regimens 
and pressure management, may not have permitted us to show 
a significant impact of rate of clearance or changes in pressure-
related parameters on reversibility of visual loss.
In the most comprehensive mechanistic study of visual loss in 
HIV-CM [5] researchers observed frequent optic nerve conduc-
tion and visual field defects compatible with raised ICP and no 
evidence of optic neuritis on MRI. The authors present evidence 
for an optic nerve compartment syndrome, caused by crypto-
coccal plugging of channels between the intracranial and the 
peri-optic subarachnoid space, as an additional cause of optic 
nerve dysfunction in CM [8]. In practice, these mechanisms 
Table 1. Univariable and Multivariable Analysis for the Association Between Age, Baseline CSF Opening Pressure, Baseline CSF Fungal Burden, and CSF 
White Cell Count and Severe Visual Loss at Presentation
Visual Acuity at CM Presentation, no. (%)
Variable (Baseline) Normal or Moderate Loss Severe Loss Unadjusted OR (95% CI) P Value Adjusted OR (95% CI) P Value*
Age       
 <50 year 356 (89.7) 41 (10.3) 1  1  
 ≥50 years 61 (81.3) 14 (18.7) 1.99 (1.03–3.87) .04 2.47 (1.22–5.05) .04
CSF Opening Pressure (cmH2O)       
 <25 200 (86.6.0) 31 (13.4) 1  1  
 25–39 98 (85.2) 17 (14.8) 1.12 (0.59–2.12)  1.28 (0.66–2.47)  
 ≥40 66 (72.5) 25 (27.5) 2.44 (1.35–4.43) .003 2.56 (1.36–4.83) .02
Fungal Burden (log10 colonies/mL)       
 <5.0 206 (88.4) 27 (11.6) 1  1  
 5.0–5.9 113 (84.3) 21 (15.7) 1.42 (0.77–2.62)  1.31  
(0.69–2.47)
 
 >6.0  62 (70.5) 26 (29.5) 3.20 (1.74–5.88) .001 3.01  
(1.58–5.70)
.003
White Cell Count (×109/L)       
 <10 249 (82.2) 54 (17.8) 1  1  
 ≥10 126 (86.3) 20 (13.7) 0.73 (0.42–1.28) .27 0.70 (0.39–1.25) .22
Abbreviations: CI, confidence interval; CM, cryptococcal meningitis; CSF, cerebrospinal fluid; OR, odds ratio. 
*Adjusted for each variable in the table. 
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may well overlap [8]: our prior work [2] and findings from this 
study suggest a relationship between fungal burden and raised 
pressure at the highest extremes of each. These 2 factors likely 
converge in an individual patient, possibly more susceptible due 
to neuroanatomical variation, rendering them either tempo-
rarily or—in the absence of intervention—permanently visually 
impaired.
CONCLUSIONS
Limitations of our cohort include the lack of visual assessment 
at baseline or reversibility at 4 weeks in the sickest of patients 
who subsequently die, possibly underestimating the prevalence 
of visual loss. We did not capture self-reported visual impair-
ment predating CM onset, which may have impacted on base-
line VA, nor were we able to exclude other conditions that can 
impair vision in this advanced HIV cohort (eg, cytomegalovirus 
retinitis). Nonetheless, our findings underscore the importance 
of interventions targeted at both fungal burden and raised ICP 
in mitigating visual loss, and they underline the need for con-
tinued efforts towards earlier diagnosis and treatment of CM, 
given that approximately half of those with severe impairment 
failed to improve despite fungicidal regimens and aggressive 
management of raised CSF pressure.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
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